| 4.56 -0.19 (-4%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.95 |
1-year : | 6.4 |
| Resists | First : | 5.09 |
Second : | 5.48 |
| Pivot price | 4.88 |
|||
| Supports | First : | 4.48 |
Second : | 3.72 |
| MAs | MA(5) : | 4.7 |
MA(20) : | 4.96 |
| MA(100) : | 5.87 |
MA(250) : | 9.06 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 16  |
D(3) : | 15.3 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 22.47 | Low : | 4.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QURE ] has closed above bottom band by 13.6%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.79 - 4.82 | 4.82 - 4.84 |
| Low: | 4.41 - 4.45 | 4.45 - 4.47 |
| Close: | 4.51 - 4.57 | 4.57 - 4.6 |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Fri, 19 Apr 2024
uniQure (NASDAQ:QURE) Share Price Passes Below 200-Day Moving Average of $6.06 - MarketBeat
Sun, 03 Mar 2024
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Sun, 03 Mar 2024
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Thu, 29 Feb 2024
A New Cause for Concern: uniQure N.V. Adds a New Innovation / R&D Risk - TipRanks.com - TipRanks
Wed, 28 Feb 2024
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Wed, 28 Feb 2024
uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 81.6 (%) |
| Shares Short | 2,480 (K) |
| Shares Short P.Month | 4,480 (K) |
| EPS | -6.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.34 |
| Profit Margin | 0 % |
| Operating Margin | -916.4 % |
| Return on Assets (ttm) | -21.8 % |
| Return on Equity (ttm) | -90.3 % |
| Qtrly Rev. Growth | -93.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.33 |
| EBITDA (p.s.) | -5.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -146 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -0.71 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 13.77 |
| Price to Cash Flow | -1.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|